Evidence reviewed: 9 November 2026. Hypothyroidism occurs when the body has insufficient thyroid-hormone activity. Common symptoms include fatigue, feeling cold, constipation, dry skin, weight changes and slowed thinking, but these symptoms are nonspecific and require appropriate laboratory interpretation. Most cases are primary hypothyroidism caused by thyroid gland dysfunction, often autoimmune Hashimoto thyroiditis. Levothyroxine (synthetic T4) is the usual first-line treatment, while management of subclinical hypothyroidism, central hypothyroidism and pregnancy differs. The 2026 American Thyroid Association pregnancy guideline specifically changed how mild thyroid-test abnormalities are approached in pregnancy, making reflex treatment of every mildly elevated TSH inappropriate [1–4].
How thyroid hormones regulate the body
The hypothalamus–pituitary–thyroid axis normally controls production of thyroxine (T4) and triiodothyronine (T3). The pituitary secretes thyroid-stimulating hormone (TSH) to regulate the gland. Peripheral tissues convert T4 to T3, which participates in metabolism, heart function, temperature regulation, nervous-system activity and growth. When the thyroid gland is underactive, TSH usually rises as the pituitary attempts to increase thyroid output [1,2].
Central hypothyroidism is the exception: pituitary or hypothalamic disease can cause low free T4 with inappropriately low or normal TSH. This is why a normal TSH does not always exclude hypothyroidism in a patient with known pituitary disease [3].
Common causes of hypothyroidism
| Cause | Mechanism | Clinical relevance |
|---|---|---|
| Hashimoto thyroiditis | Immune-mediated thyroid tissue injury, often with thyroid peroxidase antibodies. | Common cause of primary hypothyroidism; long-term replacement may be needed. |
| Thyroid surgery or radioactive iodine | Reduction or removal of functioning thyroid tissue. | Replacement is often lifelong after total thyroidectomy. |
| Thyroiditis | Transient inflammation, sometimes followed by a temporary hypothyroid phase. | Recovery is possible in selected cases. |
| Iodine deficiency or excess | Disrupts thyroid-hormone synthesis or autoregulation. | Depends on regional iodine nutrition and exposures. |
| Medications | Examples include amiodarone, lithium and certain immune therapies. | Requires medication-specific assessment and monitoring. |
| Central hypothyroidism | Pituitary or hypothalamic disease reduces appropriate TSH stimulation. | Requires free T4-based monitoring and assessment of other pituitary hormones. |
Hypothyroidism can also be congenital, and neonatal screening is important because untreated congenital deficiency can affect neurodevelopment. Adult medication and dosing guidance does not apply directly to infants or children [1].
Signs and symptoms
- Fatigue or reduced energy not explained by ordinary sleep loss.
- Cold intolerance or decreased heat production.
- Constipation and slowed bowel activity.
- Dry skin, hair thinning and sometimes brittle nails.
- Weight gain, often modest and partly related to fluid changes.
- Slower thinking, low mood or concentration problems.
- Heavy or irregular menstrual bleeding in some people.
- Slow pulse, muscle cramps or weakness in more substantial disease.
- Goiter in selected autoimmune or iodine-related conditions.
None of these symptoms proves hypothyroidism. Similar findings can occur with iron deficiency, depression, menopause, sleep apnea, adverse drug effects or chronic illness. Blood testing is used to support a diagnosis rather than prescribing thyroid hormone solely because someone feels tired.
How to interpret TSH and free T4
| Typical laboratory pattern | Likely interpretation | Next step |
|---|---|---|
| High TSH + low free T4 | Overt primary hypothyroidism. | Assess cause and generally start levothyroxine. |
| High TSH + normal free T4 | Subclinical primary hypothyroidism. | Confirm persistence; treatment depends on level, age, symptoms and circumstances. |
| Low free T4 + low or inappropriately normal TSH | Possible central hypothyroidism. | Evaluate pituitary disease and other hormones; avoid relying on TSH alone. |
| Low TSH + high free T4/T3 | Typical hyperthyroid/thyrotoxic pattern. | Evaluate Graves, nodules, thyroiditis or excess replacement. |
| Normal TSH + normal free T4 | Often euthyroid in a person with intact pituitary signaling. | Consider other causes of symptoms if clinically appropriate. |
Reference ranges differ by laboratory, age, pregnancy status and assay. Biotin supplements, some drugs, acute illness and analytical factors can interfere with thyroid tests; unexpected patterns may need repeat testing and laboratory review [1].
Hashimoto disease and thyroid antibodies
Hashimoto thyroiditis is an autoimmune process that can gradually reduce thyroid hormone production. The thyroid peroxidase antibody (TPOAb) test may support the cause and help predict progression in some patients. However, a positive antibody result without biochemical hypothyroidism does not automatically justify levothyroxine [1,4].
NICE recommends considering a single TPOAb measurement in adults with elevated TSH but advises against repeatedly testing antibody titers simply to follow therapy. The treatment target for primary hypothyroidism is generally thyroid function and wellbeing, not eliminating autoantibodies.
Subclinical hypothyroidism: when should it be treated?
For nonpregnant adults, NICE NG145 recommends considering levothyroxine when TSH is 10 mIU/L or higher on two occasions three months apart. For adults under 65 with symptoms and persistent TSH above the laboratory range but below 10 on two tests, a six-month levothyroxine trial may be considered. If symptoms do not improve despite normalized TSH, the need for treatment should be reconsidered [1].
Decision-making also considers autoimmune features, age, prior thyroid surgery, fertility planning and comorbid heart disease. A single mildly elevated TSH does not establish an irreversible condition; values can normalize, especially in older adults or after transient illness.
Levothyroxine: first-line treatment
Levothyroxine is synthetic T4. It has a long biological half-life and is converted in tissues to active T3. Most people with overt primary hypothyroidism can achieve appropriate hormone replacement with one daily dose. NICE recommends levothyroxine monotherapy as first-line treatment; routine liothyronine (T3) or desiccated animal thyroid preparations are not recommended for most patients because of uncertain additional benefit and safety concerns [1].
Do not use thyroid hormone for weight loss in a person with normal thyroid function. Excess replacement can cause palpitations, atrial fibrillation, bone loss and other effects of thyrotoxicosis.
How is the dose chosen?
For otherwise healthy adults under 65 without cardiovascular disease needing full replacement, NICE suggests considering an initial dose of approximately 1.6 micrograms/kg/day, rounded appropriately; dose selection is individualized according to weight, residual thyroid function and clinical context [1].
For adults 65 or older and patients with cardiovascular disease, NICE advises considering a lower starting dose, typically 25–50 micrograms/day, with gradual titration. Older adult dosing, frailty, pregnancy and central hypothyroidism have different goals. These are guideline examples, not instructions to calculate or self-prescribe a personal dose.
How should levothyroxine be taken?
- Use it consistently at the same time and under similar food conditions each day.
- Common advice is on an empty stomach 30–60 minutes before breakfast, or at a consistent bedtime sufficiently separated from food.
- Separate from calcium, iron supplements and some antacids, often by about four hours, because they can reduce absorption.
- Proton pump inhibitors, bile-acid binders, certain antiepileptics and other medicines may affect absorption or replacement needs.
- Follow the prescriber’s plan for missed doses, product changes and monitoring; do not compensate by taking extra tablets without advice.
Changing between brands or formulations sometimes alters thyroid function in sensitive patients, so monitor appropriately. Persistent high TSH despite apparent adherence should prompt review of administration, interactions and possible malabsorption—not automatic escalation to a very high dose.
Monitoring TSH and free T4
For primary hypothyroidism, NICE recommends aiming for TSH within the reference range without suppression. In adults, it suggests TSH measurement about every three months until stable—defined as two similar normal-range values three months apart—and annually thereafter. FT4 may be added if symptoms persist despite therapy [1].
After an individual dose change, many clinicians reassess when a new steady state has developed, often after approximately six to eight weeks, with schedule adjusted for severe longstanding disease and local guidelines. TSH recovery can be slow when pretreatment TSH was markedly elevated [1].
Central hypothyroidism: a different monitoring rule
In central hypothyroidism, low FT4 occurs because the pituitary/hypothalamus does not provide suitable stimulation. TSH is not a reliable dose target; clinicians typically titrate replacement against FT4 and clinical status, while considering other pituitary deficiencies [3].
Adrenal insufficiency must be assessed and treated before starting levothyroxine when central pituitary disease is suspected, because giving thyroid hormone can precipitate adrenal crisis in a person with untreated cortisol deficiency. Pituitary hormone evaluation requires specialist care.
2026 ATA guideline: hypothyroidism before pregnancy
The 2026 ATA pregnancy and preconception guideline recommends establishing an appropriate thyroid status before conception, and explains that treatment thresholds depend on the degree and timing of thyroid-function abnormalities [4].
For people with established overt hypothyroidism on levothyroxine, the aim is generally a TSH within range, often below 2.5 mIU/L while planning pregnancy, followed by individualized monitoring. Thyroid hormone requirements often increase in early pregnancy, so the patient should contact the treating team immediately after pregnancy is confirmed to review dose and testing. A uniform automatic dose increase may cause overtreatment in some circumstances [4].
2026 ATA: new distinctions for thyroid disease during pregnancy
| Clinical scenario | 2026 ATA approach |
|---|---|
| Overt hypothyroidism with TSH at least 6 mIU/L | Levothyroxine treatment is recommended in the appropriate confirmed setting. |
| Milder new overt hypothyroidism with TSH below 6 | Repeat confirmation within about three weeks may be considered when clinically suitable before treatment. |
| Subclinical hypothyroidism with TSH above 10 | Treat with levothyroxine. |
| Mild subclinical hypothyroidism first identified during first trimester | Levothyroxine may be considered after counseling and review. |
| Mild subclinical hypothyroidism first identified after first trimester | Guideline recommends not routinely starting levothyroxine; reassess TSH after 4–6 weeks. |
| Normal thyroid function with positive TPO antibodies only | Do not prescribe levothyroxine solely because antibodies are positive. |
These updated recommendations differ from older advice that often treated every mild TSH elevation by antibody status. Specialist and pregnancy-specific reference intervals remain important. The guideline recommends levothyroxine monotherapy in pregnancy, not liothyronine or desiccated thyroid [4].
Postpartum thyroiditis
Postpartum thyroiditis may cause a transient hyperthyroid phase followed by hypothyroidism, sometimes with recovery and sometimes with lasting low thyroid function. Symptoms can be mistaken for ordinary postpartum fatigue or mood changes. Antithyroid medications generally do not treat the hyperthyroid phase of destructive thyroiditis, but beta blockers may be used selectively for symptoms. Persistent hypothyroidism may require levothyroxine [4].
Reassessment after pregnancy, evaluation of breastfeeding medication compatibility and long-term TSH follow-up are important in selected patients, especially those with TPO antibodies or prior episodes.
Does hypothyroidism cause high cholesterol?
Yes. Untreated hypothyroidism can increase LDL-C through changes in hepatic cholesterol metabolism and LDL receptor activity. Treating confirmed hypothyroidism can improve the lipid profile, although some people still need separate dietary or lipid-lowering therapy [1].
For practical cardiovascular nutrition, see our high cholesterol diet and 2026 risk guideline. Correct thyroid status should be considered when elevated LDL-C is unexpectedly difficult to control.
Myxedema coma: an emergency
Myxedema coma is a rare, life-threatening complication of severe decompensated hypothyroidism; the patient may not literally be in a coma. Features can include marked hypothermia, profound lethargy or confusion, slow heart rate, low blood pressure, hypoventilation and hyponatremia. It requires urgent intensive hospital treatment with thyroid hormone and appropriate adrenal/supportive care.
Do not treat severe hypothermia, collapse or confusion at home by taking extra tablets. Seek emergency medical evaluation.
Common treatment errors
- Diagnosing solely from fatigue without appropriate TSH/FT4 interpretation.
- Treating every mildly high TSH without repeat confirmation or clinical context.
- Using TSH alone in central hypothyroidism.
- Taking levothyroxine together with calcium or iron and not considering absorption.
- Increasing replacement to suppress TSH when there is no specific indication.
- Using unregulated thyroid supplements or animal extracts instead of standardized treatment.
- Assuming pregnancy dosing is identical to nonpregnant dosing.
Frequently asked questions
Can hypothyroidism cause weight gain?
Yes, usually modest weight change partly involving fluid retention; many other factors also contribute.
Is levothyroxine usually lifelong?
Often, especially after complete thyroid removal or permanent Hashimoto-related loss, but transient thyroiditis can sometimes recover.
Why is TSH high even though I take levothyroxine?
Causes include missed doses, food/medicine interactions, malabsorption or an insufficient prescribed dose; review with the clinician.
Does every adult with TSH 5–8 need treatment?
No. NICE recommends repeat testing and individualized decisions; selected symptomatic adults under 65 may have a monitored trial [1].
Can a normal TSH exclude hypothyroidism in pituitary disease?
No. Central hypothyroidism can have low FT4 with a normal or low TSH [3].
Did the 2026 ATA guidance change pregnancy treatment?
Yes. It places greater emphasis on testing confirmation, timing, degree of TSH elevation and avoiding overtreatment of mild later-pregnancy abnormalities [4].
Key takeaways
Hypothyroidism is diagnosed biochemically in clinical context. For most overt primary cases, levothyroxine monotherapy restores thyroid hormone activity, with TSH monitoring. Central hypothyroidism requires FT4-guided specialist care, while subclinical disease and pregnancy require individualized thresholds. The 2026 ATA pregnancy guideline does not support automatically treating every mild TSH elevation.
References
- National Institute for Health and Care Excellence. Thyroid disease: assessment and management (NG145). NICE; accessed 9 Nov 2026.
- American Thyroid Association. Hypothyroidism: overview and treatment. ATA; accessed 9 Nov 2026.
- Persani L, Brabant G, Dattani M, et al. 2018 European Thyroid Association guidelines on diagnosis and management of central hypothyroidism. Eur Thyroid J. 2018. Full text.
- Korevaar TIM, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid. 2026. doi:10.1177/10507256261445624.
- National Institute of Diabetes and Digestive and Kidney Diseases. Hypothyroidism. NIH; accessed 9 Nov 2026.
Medical disclaimer: Educational information only. Thyroid testing and levothyroxine doses must be individualized, especially in pregnancy, heart disease or pituitary illness. Do not self-adjust thyroid hormones. Severe confusion, hypothermia, collapse or suspected adrenal crisis requires emergency medical care.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.